RSS   Newsletter   Contact   Advertise with us

Audentes Therapeutics appoints John T. Gray as SVP

Share on Twitter Share on LinkedIn
Staff Writer | San Francisco, Ca., USA | May 10, 2017
Audentes TherapeuticsMay 10, 2017, San Francisco, Ca., USA - Audentes Therapeutics, a biotechnology company, announced the appointment of John T. Gray to senior vice president and chief scientific officer.
Dr. Gray joined Audentes in 2014 as Vice President, Research and Development.

Dr. Gray joined Audentes with over 20 years of experience designing genetic therapies and vaccines, and developing manufacturing processes for those products.

Immediately prior to Audentes, Dr. Gray served as the Director of Vector Production and Development at St. Jude Children's Research Hospital where he led a team devoted to advancing gene therapy vector science.

During his tenure at St. Jude, he also worked on Chimeric Antigen Receptor modified cell therapy, lysosomal storage disorder gene therapy, and multiple hematopoietic stem/progenitor cell gene therapy projects utilizing both AAV and lentiviral vectors.

Prior to joining St. Jude, he served as the assistant director of the Harvard Gene Therapy Initiative and prior to that, worked at Pfizer Animal Health designing bacterial and viral vectors for vaccine applications.

Dr. Gray has a Bachelor of Arts degree in Biochemistry from the University of California, Berkeley, and a Ph.D. degree in Biochemistry from the University of Colorado, Boulder.